Benign Prostatic Hyperplasia (BPH) Devices Market Size 2026-2030
The benign prostatic hyperplasia (bph) devices market size is valued to increase by USD 3.29 billion, at a CAGR of 4.6% from 2025 to 2030. Shift toward minimally invasive surgical therapies (MISTs) and office-based interventions will drive the benign prostatic hyperplasia (bph) devices market.
Major Market Trends & Insights
- North America dominated the market and accounted for a 44.7% growth during the forecast period.
- By Therapy - TURP segment was valued at USD 5.28 billion in 2024
- By Type - Invasive surgery segment accounted for the largest market revenue share in 2024
Market Size & Forecast
- Market Opportunities: USD 5.58 billion
- Market Future Opportunities: USD 3.29 billion
- CAGR from 2025 to 2030 : 4.6%
Market Summary
- The Benign Prostatic Hyperplasia (BPH) Devices Market is undergoing a significant transformation, driven by a decisive move away from purely resective procedures toward anatomy-sparing technologies. This evolution is shaped by demands for treatments that offer not only effective symptom relief but also preserve quality of life, particularly sexual function.
- Innovations in minimally invasive surgical therapies, including prostatic urethral lift, water vapor thermal therapy, and robotic aquablation, are enabling procedures to migrate from hospital operating rooms to ambulatory surgical centers and office settings. This shift is supported by the development of devices like superelastic nitinol implants and advanced bipolar resection systems.
- However, the high capital equipment acquisition costs for platforms featuring image-guided precision and the complexities of securing permanent coding infrastructure present considerable hurdles.
- For a healthcare system, the decision to invest in a new robotic-assisted surgery platform involves balancing the upfront cost against long-term benefits such as improved urinary flow rate improvement, reduced surgical wait time reduction, and enhanced bph device safety profiles, all of which are critical for maintaining a competitive edge and meeting value-based care models.
What will be the Size of the Benign Prostatic Hyperplasia (BPH) Devices Market during the forecast period?
Get Key Insights on Market Forecast (PDF) Request Free Sample
How is the Benign Prostatic Hyperplasia (BPH) Devices Market Segmented?
The benign prostatic hyperplasia (bph) devices industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2026-2030, as well as historical data from 2020-2024 for the following segments.
- Therapy
- TURP
- Laser therapy
- Others
- Type
- Invasive surgery
- Minimal invasive surgery
- End-user
- Hospitals
- Specialty facilities
- Research and manufacturing
- Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Asia
- Rest of World (ROW)
- North America
By Therapy Insights
The turp segment is estimated to witness significant growth during the forecast period.
The transurethral resection of the prostate segment continues to be a foundational component of the market, serving as a clinical benchmark for luts symptom relief.
The evolution from monopolar to bipolar electrosurgery has significantly improved the procedure's safety, with data showing it reduces the risk of certain complications by over 90%, allowing for effective prostatic tissue ablation in a wider range of patients.
Despite the rise of non-resective interventional therapy, TURP maintains relevance due to established cpt code reimbursement and its proven cost-utility analysis. Health technology assessment bodies still recognize its value, especially in settings where capital-intensive technologies are not feasible.
This ensures a stable demand for the associated endoscopic instruments and supports its role in comprehensive urodynamic diagnostic systems.
The TURP segment was valued at USD 5.28 billion in 2024 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 44.7% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
See How Benign Prostatic Hyperplasia (BPH) Devices Market Demand is Rising in North America Request Free Sample
The geographic landscape of the market is characterized by varied adoption rates and clinical priorities.
North America leads in incremental growth, projected to contribute 44.7% of the global expansion, driven by favorable reimbursement for office-based interventions and the rapid uptake of minimally invasive surgical therapies.
This migration to outpatient settings is shown to reduce procedure times by up to 30%. In contrast, Europe shows strong adoption of hospital-based procedures like holmium laser enucleation, supported by robust health technology assessment protocols.
Meanwhile, Asia is the fastest-growing region, with countries like Japan and South Korea rapidly adopting premium technologies such as robotic-assisted surgery and temporary nitinol devices.
This growth is fueled by expanding healthcare access and a focus on reducing luts symptom relief wait times, making cost-utility analysis a key factor in technology procurement.
Market Dynamics
Our researchers analyzed the data with 2025 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
- The strategic landscape of the Benign Prostatic Hyperplasia (BPH) Devices Market is increasingly defined by nuanced clinical decision-making, where the choice between minimally invasive vs invasive bph surgery is paramount. Clinicians evaluating robotic bph surgery vs turp outcomes must weigh the superior durability of resection against the enhanced safety profile of robotic platforms.
- For many patients, office-based bph procedure recovery time is a critical factor, driving interest in bph treatment options for sexually active men that prioritize a swift return to daily activities. This has spurred advancements in urological endoscopic surgery and the development of the latest fda-approved bph device technologies, including non-surgical bph implant treatment options.
- The cost-effectiveness of prostatic urethral lift and other implants is a key consideration, especially in ambulatory surgical center bph procedure costs. BPH devices for treating large prostates, such as those using holmium vs thulium fiber laser for bph, offer solutions for complex cases. However, managing bph with anticoagulant therapy remains a challenge that influences technology choice.
- Ultimately, bph device reimbursement challenges 2025 and an analysis of transurethral resection complication rates continue to shape the treatment paradigm, with a focus on matching bph symptoms and corresponding device treatments to individual patient needs.
- Data shows that therapies offering bph treatment without sexual side effects have adoption rates that are over 50% higher among younger patient demographics, a crucial factor in strategic planning.
What are the key market drivers leading to the rise in the adoption of Benign Prostatic Hyperplasia (BPH) Devices Industry?
- A key market driver is the clinical and patient-driven shift toward minimally invasive surgical therapies and office-based interventions that prioritize faster recovery and functional preservation.
- Market growth is significantly driven by favorable reimbursement policies and strong patient demand for functional preservation.
- The establishment of permanent coding infrastructure for novel minimally invasive surgical therapies is a critical catalyst; technologies with dedicated cpt code reimbursement see adoption rates increase by over 60% within two years of implementation.
- This financial stability incentivizes providers to invest in platforms for prostatic urethral lift and holmium laser enucleation.
- Furthermore, patient preference is a powerful driver, with clinical data showing that over 75% of eligible men choose treatments that prioritize sexual function preservation.
- This demand fuels the growth of anatomy-sparing technologies and direct-to-patient educational campaigns that highlight superior patient-reported outcomes, reinforcing the importance of positive clinical trial endpoints.
What are the market trends shaping the Benign Prostatic Hyperplasia (BPH) Devices Industry?
- The integration of artificial intelligence and robotic precision is a significant market trend. This convergence aims to standardize surgical outcomes and enhance patient safety across various BPH interventions.
- Key market trends revolve around the integration of intelligent systems and the migration of care to outpatient settings. The adoption of robotic-assisted surgery platforms, which leverage firstassist ai software and the aquabeam intelligence cloud, is standardizing complex procedures like prostatic tissue ablation.
- These systems deliver a level of image-guided precision that has been shown to reduce surgical planning time by over 50%. Concurrently, the shift toward office-based bph treatment is accelerating, with ambulatory surgical centers now performing a significant volume of procedures.
- This trend is supported by the development of compact devices for water vapor thermal therapy and mechanical dilation, which lower capital expenditure scrutiny and reduce overall healthcare costs by nearly 35% compared to inpatient care, enhancing the overall bph device safety profile.
What challenges does the Benign Prostatic Hyperplasia (BPH) Devices Industry face during its growth?
- Reimbursement volatility and policy uncertainty represent a key challenge, impacting technology adoption rates and the commercial viability of novel BPH therapies.
- The market faces significant headwinds from reimbursement instability and stringent regulatory oversight. For example, a recent 2.83% reduction in the physician fee schedule directly eroded the profitability of office-based interventions, threatening the financial viability of the razor-and-blade model for many devices. Such budget neutrality adjustments create uncertainty and can slow capital equipment acquisition.
- Simultaneously, the intensifying burden of post-market surveillance under frameworks like the medical device regulation (MDR) has increased compliance costs by an estimated 20%. This diverts resources from innovation and elevates the risk associated with product recalls, as highlighted in recent recall index reports. These economic and regulatory pressures demand robust strategies to demonstrate long-term value and ensure flawless quality control.
Exclusive Technavio Analysis on Customer Landscape
The benign prostatic hyperplasia (bph) devices market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the benign prostatic hyperplasia (bph) devices market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape of Benign Prostatic Hyperplasia (BPH) Devices Industry
Competitive Landscape
Companies are implementing various strategies, such as strategic alliances, benign prostatic hyperplasia (bph) devices market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
biolitec AG - Robotic-assisted aquablation systems for minimally invasive BPH treatment utilize image-guided, heat-free waterjet technology to deliver precise and standardized surgical outcomes.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- biolitec AG
- Boston Scientific Corp.
- Coloplast AS
- CONMED Corp.
- Cook Group Inc.
- Dornier MedTech GmbH
- ForTec Medical
- KARL STORZ SE and Co. KG
- Laborie
- Lumenis Be Ltd.
- Medtronic Plc
- Olympus Corp.
- OmniGuide Holdings Inc.
- Pnn Medical AS
- PROCEPT BioRobotics Corp.
- Quanta System S.p.A.
- Richard Wolf GmbH
- SonaCare Medical LLC
- Teleflex Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Benign prostatic hyperplasia (bph) devices market
- In August, 2024, PROCEPT BioRobotics Corporation received 510(k) clearance from the United States Food and Drug Administration for the HYDROS Robotic System, its next-generation platform for Aquablation therapy featuring AI-driven software.
- In November, 2024, Olympus Corporation announced that the American Medical Association had issued new Category I CPT codes for the iTind procedure, which became effective in January 2025, securing a permanent reimbursement pathway.
- In February, 2025, Laborie Medical Technologies announced the strategic expansion of its Optilume BPH Catheter System into key Asia-Pacific markets, including Japan, to support the growing demand for office-based treatments.
- In May, 2025, Teleflex Incorporated initiated a new direct-to-patient educational campaign focused on the lifestyle preservation benefits of the UroLift System, highlighting real-world data on sexual function preservation.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Benign Prostatic Hyperplasia (BPH) Devices Market insights. See full methodology.
| Market Scope | |
|---|---|
| Page number | 294 |
| Base year | 2025 |
| Historic period | 2020-2024 |
| Forecast period | 2026-2030 |
| Growth momentum & CAGR | Accelerate at a CAGR of 4.6% |
| Market growth 2026-2030 | USD 3286.1 million |
| Market structure | Fragmented |
| YoY growth 2025-2026(%) | 4.4% |
| Key countries | US, Canada, Mexico, Germany, UK, France, Italy, Spain, The Netherlands, China, Japan, India, South Korea, Indonesia, Singapore, Brazil, Saudi Arabia, UAE, Argentina, Turkey, South Africa, Egypt and Chile |
| Competitive landscape | Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Research Analyst Overview
- The Benign Prostatic Hyperplasia (BPH) Devices Market is characterized by intense innovation centered on improving clinical outcomes and patient experience. A dominant theme is the development of anatomy-sparing technologies and non-resective interventional therapy, which directly challenge traditional methods like transurethral resection of the prostate and procedures using plasma vaporization electrodes.
- The commercial success of prostatic urethral lift and water vapor thermal therapy has set a new standard. Boardroom-level strategy is now focused on the next wave of innovation, including the Zenflow spring implant, superelastic nitinol implants, and drug-eluting balloon catheters. This requires significant investment in technologies such as firstassist ai software and advanced tissue control systems.
- For instance, data shows devices enabling catheter-free recovery achieve market penetration twice as fast, forcing a re-evaluation of R&D priorities. The push for office-based interventions is also driving demand for advanced endoscopic visualization technologies and compact bipolar resection systems.
- The competitive landscape requires a portfolio that spans from high-intensity focused ultrasound and robotic aquablation to simple mechanical dilation and prostatic stent solutions, all while navigating a complex regulatory environment.
What are the Key Data Covered in this Benign Prostatic Hyperplasia (BPH) Devices Market Research and Growth Report?
-
What is the expected growth of the Benign Prostatic Hyperplasia (BPH) Devices Market between 2026 and 2030?
-
USD 3.29 billion, at a CAGR of 4.6%
-
-
What segmentation does the market report cover?
-
The report is segmented by Therapy (TURP, Laser therapy, and Others), Type (Invasive surgery, and Minimal invasive surgery), End-user (Hospitals, Specialty facilities, and Research and manufacturing) and Geography (North America, Europe, Asia, Rest of World (ROW))
-
-
Which regions are analyzed in the report?
-
North America, Europe, Asia and Rest of World (ROW)
-
-
What are the key growth drivers and market challenges?
-
Shift toward minimally invasive surgical therapies (MISTs) and office-based interventions, Reimbursement volatility and policy uncertainty
-
-
Who are the major players in the Benign Prostatic Hyperplasia (BPH) Devices Market?
-
biolitec AG, Boston Scientific Corp., Coloplast AS, CONMED Corp., Cook Group Inc., Dornier MedTech GmbH, ForTec Medical, KARL STORZ SE and Co. KG, Laborie, Lumenis Be Ltd., Medtronic Plc, Olympus Corp., OmniGuide Holdings Inc., Pnn Medical AS, PROCEPT BioRobotics Corp., Quanta System S.p.A., Richard Wolf GmbH, SonaCare Medical LLC and Teleflex Inc.
-
Market Research Insights
- Market dynamics are increasingly shaped by a focus on quantifiable outcomes and economic efficiency, compelling a shift toward advanced therapeutic solutions. The adoption of treatments in ambulatory surgical centers is accelerating, as these sites can reduce procedural costs by up to 35% compared to traditional hospital settings.
- Furthermore, devices that demonstrate superior sexual function preservation see adoption rates nearly 25% higher, reflecting strong patient-reported outcomes influence. This trend is reinforced by clinical guideline updates that prioritize a strong bph device safety profile.
- As a result, navigating cpt code reimbursement and aligning with value-based care models have become critical for commercial success, influencing everything from capital equipment acquisition strategies to direct-to-patient marketing campaigns. The focus on real-world evidence for bph is also intensifying, as payers scrutinize long-term efficacy to justify coverage.
We can help! Our analysts can customize this benign prostatic hyperplasia (bph) devices market research report to meet your requirements.